COSMO Pharmaceuticals N.V.
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
COPN | SW
Overview
Corporate Details
- ISIN(s):
- NL0011832936
- LEI:
- 724500OX0EBQRYTVV639
- Country:
- Netherlands
- Address:
- Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
- Website:
- https://www.cosmopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for gastroenterology, dermatology, and healthtech. The company's therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, utilizing its proprietary MMX® technology. In addition to its own pipeline, Cosmo provides manufacturing services to other pharmaceutical companies. These services cover the production of solid, semi-solid, and liquid oral medicines and include process assessment, technology transfer, stability testing, market release, and regulatory documentation support.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-16 01:00 |
Cosmo Pharmaceuticals reports record results for 2022, preliminary results exce…
|
English | 11.4 KB | ||
| 2023-02-16 01:00 |
Cosmo Pharmaceuticals vermeldet Rekordergebnisse für 2022, vorläufige Ergebniss…
|
German | 12.6 KB | ||
| 2022-12-21 01:00 |
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi…
|
English | 13.9 KB | ||
| 2022-12-21 01:00 |
Cosmo und Hyphens geben die Unterzeichnung von Lizenz- und Liefervereinbarungen…
|
German | 15.0 KB | ||
| 2022-12-14 01:00 |
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
|
English | 13.3 KB | ||
| 2022-12-14 01:00 |
Cosmo gibt erfolgreiche klinische Phase III-Studie mit Lumeblue™ in China bekan…
|
German | 14.7 KB | ||
| 2022-10-20 02:00 |
Cosmo announces FDA grants orphan-drug designation of
rifamycin for treatment o…
|
English | 8.2 KB | ||
| 2022-10-20 02:00 |
Cosmo erhält von der FDA den Orphan-Drug-Status für
Rifamycin zur Behandlung v…
|
German | 9.0 KB | ||
| 2022-10-12 02:00 |
GI Genius™ named to FORTUNE 2022 “Change the World” list
|
English | 7.7 KB | ||
| 2022-10-12 02:00 |
GI Genius™ wurde in die FORTUNE 2022-Liste «Change the World» aufgenommen
|
German | 8.5 KB | ||
| 2022-10-06 02:00 |
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Geniu…
|
English | 7.8 KB | ||
| 2022-10-06 02:00 |
Medtronic erhält Auftrag des US-Ministeriums für Veteranen-Angelegenheiten zur …
|
German | 8.3 KB | ||
| 2022-10-04 02:00 |
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement f…
|
English | 11.3 KB | ||
| 2022-10-04 02:00 |
Cosmo und InfectoPharm geben Unterzeichnung einer Lizenz- und Vertriebsvereinba…
|
German | 12.2 KB | ||
| 2022-07-28 02:00 |
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
|
English | 13.9 KB |
Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for COSMO Pharmaceuticals N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
